1
Liversidge Gary G, Cundy Kenneth C, Bishop John F, Czekai David A: Surface modified drug nanoparticles.. Sterling Winthrop, August 19, 1992: EP0499299-A2 (146 worldwide citation)

Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions conta ...


2
Liversidge Gary G C O Sterling, Liversidge Elaine C O Sterling, Sarpotdar Pramod C O Sterling: Surface modified anticancer nanoparticles.. Sterling Winthrop, January 5, 1994: EP0577215-A1 (74 worldwide citation)

Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles exhibit reduced ...


3
Vaghefi Farid, Liversidge Gary G, Ruddy Stephen B, Cooper Eugene R: Abuse-resistant pharmaceutical compositions. Verion, Elan Corporation, Vaghefi Farid, Liversidge Gary G, Ruddy Stephen B, Cooper Eugene R, SAVITZKY Martin F, April 1, 2004: WO/2004/026262 (63 worldwide citation)

An abuse-resistant controlled release pharmaceutical composition comprising a pharmaceutically effective amount of discrete particles of an active capable of abuse, wherein surfaces of said particles are wetted with a water insoluble coating material, and preferably wherein said composition comprise ...


4
Liversidge Gary G, Cundy Kenneth C, Bishop John F, Czekai David A: X-ray contrast compositions useful in medical imaging.. Sterling Winthrop, August 12, 1992: EP0498482-A2 (55 worldwide citation)

An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, and a pharmace ...


5
Liversidge Gary G, Conzentino Philip, Cundy Kenneth, Sarpotdar Pramod P: Surface modified nsaid nanoparticles.. Eastman Kodak Co, March 29, 1995: EP0644755-A1 (15 worldwide citation)

Dispersible particles consisting essentially of a crystalline NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm. Pharmaceutical compositions containing the particles exhibit reduced gastric ...


6
Cunningham James, Merisko Liversidge Elaine, Cooper Eugene R, Liversidge Gary G: Milling microgram quantities of nanoparticulate candidate compounds. Elan Pharma International, Cunningham James, Merisko Liversidge Elaine, Cooper Eugene R, Liversidge Gary G, SIMKIN Michele M, July 15, 2004: WO/2004/058216 (7 worldwide citation)

The present invention is directed to a method of milling small quantities of one or more candidate compounds to reduce the particle size of at least one candidate compound to about 2 microns or less. The apparatus used for the milling process can be one or more multi-well plates, or any other suitab ...


7
Liversidge Gary G, Jenkins Scott: Nanoparticulate ebastine formulations. Elan Pharma Int, March 19, 2008: EP1898882-A2 (1 worldwide citation)

The invention is directed to compositions comprising at least one nanoparticulate H 1-histamine receptor antagonist, such as ebastine or a salt or derivative thereof, having improved dissolution rate providing a faster onset of drug availability. The nanoparticulate H1-histamine receptor antagonist ...


8
Jenkins Scott, Liversidge Gary G: Nanoparticulate imatinib mesylate formulations. Elan Pharma International, Jenkins Scott, Liversidge Gary G, SIMKIN Michele M, December 14, 2006: WO/2006/133046 (1 worldwide citation)

The present invention is directed to a nanoparticulate compositions of imatinib mesylate, or a salt or derivative thereof, having improved pharmacokinetic profiles and reduced fed/fasted variability. The nanoparticulate imatinib mesylate particles of the composition have an effective average particl ...


9
Liversidge Gary G, Jenkins Scott: Nanoparticulate ebastine formulations. Elan Pharma International, Liversidge Gary G, Jenkins Scott, SIMKIN Michele M, December 21, 2006: WO/2006/135689 (1 worldwide citation)

The invention is directed to compositions comprising at least one nanoparticulate H 1-histamine receptor antagonist, such as ebastine or a salt or derivative thereof, having improved dissolution rate providing a faster onset of drug availability. The nanoparticulate H1-histamine receptor antagonist ...


10